A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis - No Study Results Posted

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)

This study has been completed.

Study NCT00513370 Information provided by Abbott

First Received: August 6, 2007 Last Updated: January 16, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)